Establishment Labs Holdings Inc. filings document regulatory disclosures for a British Virgin Islands medical technology issuer listed on Nasdaq. Its Form 8-K reports cover operating results and financial condition, preliminary financial information, Regulation FD presentation materials, credit-agreement amendments, senior secured term-loan obligations, and other material definitive agreements.
The company’s proxy materials disclose board matters, executive compensation, equity awards, shareholder voting items, and governance practices. Together, the filings describe the Motiva-focused breast aesthetics and reconstruction business, capital structure, debt arrangements, forward-looking-statement disclosures, and recurring corporate reporting obligations.
Establishment Labs Holdings Inc. reported third-quarter 2026 revenue of $72.0 million, up 33.9% from $53.8 million in the prior-year quarter.
U.S. revenue increased 119.0% to $26.0 million, while OUS revenue increased 9.7% to $46.0 million. GAAP gross margin was 69.1%, compared with 70.1%; GAAP net loss was $10.7 million, versus $11.1 million. Adjusted EBITDA was $6.4 million, compared with $1.2 million a year earlier. Operating cash flow was approximately $7.7 million, and free cash flow was $5.1 million, the first positive free-cash-flow quarter in the company’s history.
For full-year 2026, the company raised revenue expectations to more than $274 million, from prior guidance of $269 million to $271 million. It expects adjusted gross margin of approximately 70.7%, adjusted operating expenses of $195 million to $200 million, and positive Adjusted EBITDA. The company also reported FDA approval for additional smaller Motiva implant sizes; FDA review of Motiva for breast reconstruction was progressing in line with expectations. It expects 25% growth and positive cash flow in fiscal 2027.
Establishment Labs Holdings Inc., through its wholly owned subsidiary Establishment Labs, S.A. (ELSA), entered Amendment No. 3 to the Master Supply Agreement with NuSil Technology LLC, effective January 1, 2027. The amendment extends the initial term from December 31, 2026, to December 31, 2031, with automatic renewals for successive one-year terms, up to five, unless ELSA or NuSil provides written notice no later than December 31 of the year before the initial or then-current renewal term expires. It also revises specified provisions covering NuSil’s manufacture and sale of medical-grade silicone for specified ELSA products, payment terms, business continuity, intellectual property and pricing.
Leslie Gillin, a director of Establishment Labs Holdings Inc. (ESTA), received a compensation-related award of 262 common shares on September 30, 2026, in lieu of a quarterly cash retainer. The reported price was $64.17 per share, and Gillin reported direct holdings of 18,856 shares following the award. The shares were issued under the 2018 Equity Incentive Plan.
Establishment Labs Holdings Inc. director Edward J. Schutter acquired 253 common shares on September 30, 2026, elected in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy. The shares were issued under the 2018 Equity Incentive Plan, with their value based on the closing price on the last trading day of the quarter: $64.17 per share. Schutter directly held 178,205 shares after the acquisition.
Establishment Labs Holdings Inc. (ESTA) director Nicholas Sheridan Lewin acquired 389 common shares on September 30, 2026, elected in lieu of a quarterly cash retainer under the Outside Director Compensation Policy. The shares were issued pursuant to the 2018 Equity Incentive Plan, at $64.17 per share, based on the closing price on the quarter’s last trading day. Lewin held 1,080,349 common shares directly following the acquisition.
Establishment Labs Holdings Inc. director Bryan Slotkin acquired 253 common shares on September 30, 2026, elected in lieu of a quarterly cash retainer under the Outside Director Compensation Policy. The shares were issued pursuant to the company's 2018 Equity Incentive Plan and priced at $64.17 per share, based on the closing price on the last trading day of the quarter. He directly held 33,052 common shares after the transaction.
Establishment Labs Holdings Inc. director Ann Custin acquired 301 common shares on September 30, 2026, at $64.17 per share, bringing the directly held total to 24,626 shares.
Custin elected to receive the shares in lieu of a quarterly cash retainer under the Outside Director Compensation Policy. The shares were issued under the 2018 Equity Incentive Plan, and the share amount was determined based on the closing price on the quarter’s last trading day.
ESTABLISHMENT LABS HOLDINGS INC. (ESTA) reported an insider equity transaction by Chief Executive Officer and director Filippo Caldini. On 2026-08-20, 682 Common Shares were withheld by the company to cover tax withholding obligations arising from the vesting of previously granted restricted stock units. This was reported as a code F transaction (payment of tax liability by delivering or withholding securities), and Caldini’s directly held position after this withholding was 48,829 Common Shares.
Establishment Labs Holdings Inc., a medical device company focused on Motiva silicone breast implants, reported strong top-line growth while remaining unprofitable for the period ended June 30, 2026. Revenue reached $67.5 million in the quarter and $127.4 million for the first half of 2026, up 31.7% and 37.5%, respectively, versus 2025. Growth was driven mainly by the U.S. launch, with U.S. sales rising sharply and a more favorable geographic and product mix lifting gross margin to 70.6% in Q2 and 70.7% year-to-date.
Operating loss narrowed to $4.3 million in Q2 and $10.8 million for the first half, while net loss improved to $11.7 million in Q2 and $25.1 million year-to-date, or $0.39 and $0.84 per share. Operating cash outflow improved but remained negative at $20.9 million for the first half. Cash stood at $71.2 million and accumulated deficit at $520.9 million, with shareholders’ equity of $21.6 million. The company refinanced and upsized its Oaktree term loan into a new facility of up to $300 million, with $265 million funded and no principal due until 2031, increasing outstanding debt to $271.6 million. Management states it is in compliance with debt covenants and believes existing cash and cash generation can cover at least the next 12 months, while it continues to pursue patent litigation in multiple jurisdictions with outcomes not yet determinable.
Establishment Labs Holdings Inc. reported strong second-quarter 2026 growth, with revenue of $67.5 million, up 31.7% year over year and 12.8% sequentially. Motiva USA revenue rose to $24.7 million from $10.3 million a year earlier, and minimally invasive revenue reached $12.1 million. Gross margin improved to 70.6% from 68.8%, helped by higher-margin U.S. sales and its minimally invasive platform.
Loss from operations narrowed to $4.3 million from $14.1 million, and net loss improved to $11.7 million, or $0.39 per share. Adjusted EBITDA turned positive at $3.7 million versus a loss of $8.5 million in 2025. Cash and cash equivalents were $71.2 million as of June 30, 2026. Reflecting this performance, full-year 2026 revenue guidance was raised to $269–$271 million, up from $266.5–$268.5 million.